Related references
Note: Only part of the references are listed.EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer
S. H. Choi et al.
ONCOGENE (2007)
Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer
Ilaria Bellezza et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain
Jeffrey C. Lee et al.
PLOS MEDICINE (2006)
Novel mutations of epidermal growth factor receptor in localized prostate cancer
Diah A. Douglas et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2006)
EGF-ERBB signalling: towards the systems level
Ami Citri et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Xuewu Zhang et al.
CELL (2006)
EGF receptor mutations in lung cancer: From humans to mice and maybe back to humans
Carlos L. Arteaga
CANCER CELL (2006)
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials
DW Bell et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants
H Greulich et al.
PLOS MEDICINE (2005)
Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck
JW Lee et al.
CLINICAL CANCER RESEARCH (2005)
Somatic mutations of epidermal growth factor receptor in colorectal carcinoma
H Nagahara et al.
CLINICAL CANCER RESEARCH (2005)
Stable expression of constitutively-activated STAT3 in benign prostatic epithelial cells changes their phenotype to that resembling malignant cells
Hosea F. Huang et al.
MOLECULAR CANCER (2005)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways
R Sordella et al.
SCIENCE (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
ErbB1 and prostate cancer:: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002
N Torring et al.
PROSTATE (2003)
Epidermal growth factor receptor: mechanisms of activation and signalling
RN Jorissen et al.
EXPERIMENTAL CELL RESEARCH (2003)
ErbB receptors: possible therapeutic targets in prostate cancer?
HL Ratan et al.
BJU INTERNATIONAL (2003)
Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice
F DeMiguel et al.
PROSTATE (2002)
Ligand-independent oncogenic transformation by the EGF receptor requires kinase domain catalytic activity
AJ Danielsen et al.
EXPERIMENTAL CELL RESEARCH (2002)
Interleukin-6 is an autocrine growth factor in human prostate cancer
D Giri et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Share Paper
